AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05585866
Drug: Anesthesia Agent
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The two anesthetic modalities included intravenous propofol anesthesia and sevoflurane gas anesthesia administered according to standard clinical praxis.
Trial: NCT06003608
Drug: Levodopa-Carbidopa Immediate Release
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, Levodopa-Carbidopa Immediate Release
Trial: NCT05280028
Drug: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estradiol valerate 1 mg/medroxyprogesterone acetate 2.5 mg per day
Trial: NCT06061146
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 immunotherapy
Trial: NCT06061146
Drug: Arm A
RxNorm normalized name: Warm antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT06061146
Drug: Arm B
RxNorm normalized name: arm brace
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT06414408
Drug: Doxycycline Pill
RxNorm normalized name: doxycycline Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg Dose
Trial: NCT04589650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo once daily up to week 16.
Trial: NCT06143878
Drug: JNJ-77242113 Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-77242113 matching placebo will be administered orally.
Trial: NCT04937101
Drug: Chlorpheniramine-Codeine
RxNorm normalized name: chlorpheniramine-codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: When the filter tester is sensitive, he opened the random letter group envelope to the notification letter manager and jointly confirmed the classification of the message group. The test group used the chlorpheniramine beacon, the physiological surface was used, and the local lesions of fine particles were used in the focus. Injection therapy. No form of anesthesia is used during injection. A total of injection treatment, at intervals, each treatment and the last treatment, treatment and safety after 1 month.
Trial: NCT05226923
Drug: KSP-1007
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single and multiple doses, intravenous administration
Trial: NCT06012097
Drug: Diclofenac gel
RxNorm normalized name: diclofenac Topical Gel
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: using diclofenac as a comparator
Trial: NCT05906628
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream is a topical formulation applied as a thin film to affected areas.
Trial: NCT05361408
Drug: Zoledronic acid, once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 5mg zoledronic acid, once
Trial: NCT05227937
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patient will be treated with amikacin 15 mg/kg IV or IM, based on actual body weight; for patients \>120% of IBW, we will use AdjBW (IBW + 0.4(ABW-IBW)) rounded to nearest 50 mg. Patients who already have an IV will receive the medication IV, otherwise the dose will be given IM.
Trial: NCT05889273
Drug: ML-004 (IR)/(ER) tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ML-004 once daily.
Trial: NCT04787848
Drug: Relistor Injectable Product
RxNorm normalized name: Relistor Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relistor is a peripherally acting opioid receptor antagonist approved by the FDA for relief of opioid-induced constipation
Trial: NCT04278963
Drug: YinHu QingWen Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YinHu QingWen Decoction (Granula) consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The decoction granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Trial: NCT04991909
Drug: HRS4800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS4800
Trial: NCT04991909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04311632
Drug: Corticosteroids (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Concomitant Immunosuppression
Trial: NCT05387525
Drug: Diclofenac Sodium 3% Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will apply diclofenac dodium 3% gel twice daily for 60 to 90 days.
Trial: NCT04079088
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT04079088
Drug: BIIB061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06194188
Drug: Subcutaneous injection of CU-20401
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reconstitute the product with 0.9% sodium chloride solution for injection, respectively, before use, for a single subcutaneous injection in the submental fat area.
Trial: NCT05424380
Drug: GSK3745417
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK3745417 will be administered
Trial: NCT06207981
Drug: induction chemotherapy (mDCF)
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy consists of mDCF administered every 2 weeks:~* Docetaxel (40 mg/m², day 1),~* Cisplatin (40 mg/m², day 1)~* 5-FU (1200 mg/m²/day IV for 2 days)
Trial: NCT06491940
Drug: Losartan + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given Losartan LS (50 mg per day) and Hydrochlorothiazide (HCTZ) 12.5 mg per day as a combination therapy.
Trial: NCT05660863
Drug: MN-08 24 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this cohort will receive 12 mg MN-08 tablets b.i.d. for a total daily dose of 24 mg or matching placebo for 6 consecutive days, and the last dose (12 mg) on the morning of Day 7.
Trial: NCT05660863
Drug: MN-08 60 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in this cohort will receive 30 mg MN-08 tablets b.i.d. for a total daily dose of 60 mg or matching placebo tablets for 6 consecutive days, and the last dose (30 mg) on the morning of Day 7.
Trial: NCT05360446
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.
Trial: NCT05762107
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives Placebo by subcutaneous injection daily for 28 days
Trial: NCT05762107
Drug: ZT-01, 7 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives ZT-01 7 mg by subcutaneous injection daily for 28 days
Trial: NCT05762107
Drug: ZT-01, 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives ZT-01 15 mg by subcutaneous injection daily for 28 days
Trial: NCT05762107
Drug: ZT-01, 22 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives ZT-01 22 mg by subcutaneous injection daily for 28 days
Trial: NCT06002230
Drug: Homeopathic medicines
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Globules were administered orally..
Trial: NCT04880187
Drug: AXA1125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AXA1125 administered BID with or without food
Trial: NCT04880187
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo administered BID with or without food
Trial: NCT05656495
Drug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate intramuscularly
RxNorm normalized name: D-alanyl-3-(2-naphthyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: lyophilizate for preparation of solution for intramuscular administration 1 mg 1 time per day for 10 days
Trial: NCT05005494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of NaCl (sodium chloride) 0.9% (placebo eq. 0.5ml/kg of NaCl 0.9%)
Trial: NCT05656495
Drug: Tyrosyl-D-alanyl-glycyl-phenylalanyl-leucyl-arginine succinate inhaled
RxNorm normalized name: D-alanyl-3-(2-naphthyl)-d-alanyl-l-alanyl-l-tryptophyl-d-phenylalanyl-l-lysinamide
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: lyophilizate for preparation of solution for inhalation administration 10 mg 1 time per day for 10 days
Trial: NCT05656495
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The administration of 'StandardTherapy' drugs was done according to the regimen recommended in the 'COVID-19TreatmentGuidelines'(current version)
Trial: NCT04951076
Drug: BNC210
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNC210 900 mg twice daily (b.i.d.) for 12 weeks
Trial: NCT04951076
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily (b.i.d.) for 12 weeks
Trial: NCT05182476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT06191744
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Injection
Trial: NCT06191744
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV Injection
Trial: NCT05787873
Drug: SIPS-2209-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05787873
Drug: SIPS-2209-2, SIPS-2209-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QD, PO
Trial: NCT05764057
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily on top of standard of care as recommended in current guidelines\* for 6 months (control group)~\*All patients will receive optimal medical therapy (including antithrombotic, beta-blockers, statins, angiotensin converting enzyme inhibitors or angiotensin receptor blocker or sacubitril/valsartan, diuretics, antagonists of the mineralocorticoid receptor) according to their clinical condition as recommended.
Trial: NCT00005921
Drug: L-743,872
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05535959
Drug: VX-121/TEZ/D-IVA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet for oral administration.
Trial: NCT04710381
Drug: IMUNOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The intervention consists of the administration of IMUNOR as prevention against COVID-19 disease
Trial: NCT04843449
Drug: ASC40
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT01151930
Drug: SCB01A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
Trial: NCT05288881
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo administered by IV infusion.
Trial: NCT04226690
Drug: matched placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will self-administer the assigned study medication daily at home after pickup and will be tested using medication compliance procedures. Subjects will visit the center 2 times in the 7-day period on days 1 and 7 for blood draws to assess medication compliance.
Trial: NCT05242692
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refer to either S-ketamine or Dexmedetomidine
Trial: NCT05301075
Drug: Rhomboid Intercostal and Sub-Serratus block
RxNorm normalized name: Fucus serratus extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhomboid Intercostal and Sub-Serratus block under ultrasound guidance
Trial: NCT04783051
Drug: Pyramax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent screening using ultra-sensitive malaria Rapid Diagnostic test and treatment using Pyronaridine - Artesunate (PYRAMAX®)
Trial: NCT06370754
Drug: JS001
RxNorm normalized name: Janus Kinase Inhibitor JS001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg by IV infusionevery 3 weeks (Q3W), given on cycle day 1.
Trial: NCT06370754
Drug: Leucovorin (LV)
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400mg/m\^2, intravenously, over 30 min on day 1, Q2W.
Trial: NCT05541276
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin for injection 1 mg/mL
Trial: NCT05818852
Drug: VX-548 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration.
Trial: NCT06506175
Drug: HRS9531 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRS9531 tablets
Trial: NCT05352815
Drug: IcoSema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.
Trial: NCT05873881
Drug: Thiamine Mononitrate 300 mg
RxNorm normalized name: Thiamine Mononitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine Mononitrate 300 mg daily
Trial: NCT06569394
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in this Arm will take a medically inert placebo. Participants will take medication by mouth with food in the morning and evening.
Trial: NCT06560515
Drug: Vaginal Dinoprostone
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: induction of labour in women with postdate pregnancy with vaginal dinoprostone vs. vaginal misoprostol
Trial: NCT05666336
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is permitted which can be interchangeable with mycophenolate mofetil or tacrolimus. It will be given by oral administration of 0.8g/month for 24 weeks.
Trial: NCT02712151
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT06324006
Drug: LIB-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIB-01 oral suspension
Trial: NCT04878770
Drug: Topical corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroids (TCS) are registered for patients of all ages, and are together with emollients, the pillars in the basic treatment of atopic dermatitis. In this study, patients in both the intervention groups and control group are treated with daily emollients and a TCS of moderate to high potency if needed. Rescue medication with TCS of higher potency may be prescribed if basic therapy is inadequate in controlling AD symptoms.
Trial: NCT05010122
Drug: Decitabine and Cedazuridine
RxNorm normalized name: cedazuridine / decitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04728061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously-infused vehicle.
Trial: NCT05492630
Drug: HEC73077 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Trial: NCT05492630
Drug: HEC73077 placebo tablets
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Trial: NCT05589792
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo before sleep for 3 nights before the study (inclusive)
Trial: NCT05375604
Drug: CDK-004
RxNorm normalized name: Cyclin-dependent kinase (CDK) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASO-STAT6 exosome administered Intravenously
Trial: NCT01422148
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
Trial: NCT05354583
Drug: Appropriate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with at least 3 antibiotics, which the pathogen is susceptible to based on in vitro drug susceptibility test, in the initial phase of the treatment
Trial: NCT04845321
Drug: VNRX-9945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Trial: NCT04845321
Drug: Placebo for VNRX-9945
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: One dose except food effect cohort (receives two doses) Part 2: 14 doses (once a day for 14 days)
Trial: NCT04188574
Drug: BB2603-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with topical spray twice-daily (BID) BB2603-1: 0.01% terbinafine
Trial: NCT04188574
Drug: BB2603-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with topical spray twice-daily (BID) BB2603-10: 0.1% terbinafine
Trial: NCT01268709
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05068466
Drug: INCB054707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT05068466
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered Orally
Trial: NCT05040880
Drug: Telmione plus 80/12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Trial: NCT05040880
Drug: Micardis plus 80/12.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference drug (Fixed-dose combination drug of telmisartan 80mg and hydrochlorothiazide 12.5mg)
Trial: NCT00000171
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00433225
Drug: Prednisolone Acetate
RxNorm normalized name: Prednisolone Acetate
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00433225
Drug: Ketorolac 0.4%
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05442151
Drug: PET/CT ([F-18]FAPI-74)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PET/CT using \[18F\] FAPI-74 injection
Trial: NCT06353061
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dosage of cisplatin is 40 mg/m2, administered once weekly during radiotherapy for a duration of 5 weeks. Prior to and following cisplatin administration, 1-2 liters of fluid should be given for adequate hydration. Treatment should continue until disease progression or intolerable toxicity occurs.
Trial: NCT04093505
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation \& Maintenance therapy Placebo 100mg on days 4 to 27
Trial: NCT06278545
Drug: modified FOLFORINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment every 14 days :~* Irinotecan 180mg/m² as a 2-hour IV infusion~* Oxaliplatin 85 mg/m² as a 2-hour IV infusion~* Folinic acid 400 mg/m² as 2-hour IV infusion, in Y with oxaliplatin~* 5-FU 2400 mg/m² as a continuous IV infusion over 46 hours
Trial: NCT06278545
Drug: Modified FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One treatment every 14 days:~* Oxaliplatin 85 mg/m by IV infusion over 2 hours~* Folinic acid: 400 mg/m² or 200 mg/m² if laevorotatory form by IV infusion over 2 hours, in Y with oxaliplatin~* 5FU bolus: 400 mg/m² per 10-minute IV infusion~* 5 FU continuous 2400 mg/m² by IV infusion over 46 hours
Trial: NCT05636592
Drug: immunotherapy
RxNorm normalized name: Dog immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: statin combined with immunotherapy
Trial: NCT06231745
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) is an anti-metabolite most commonly used in chemotherapy and immunosuppressant in auto-immune diseases. This activity describes the indications, action, and contraindications for Methotrexate as a valuable agent in treating a wide variety of diseases.
Trial: NCT06439212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
Trial: NCT05121480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT05685173
Drug: REGN5837
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN5837 will be administered by IV infusion